Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 22 Mar 2021
Early benefit assessment - the whole spectrum
19 March 2021 - IQWiG evaluated a total of 24 manufacturer dossiers punctually for the dates March 1 and March 15. ...
Posted by Michael Wonder on 22 Mar 2021
Oakrum Pharma and Aucta Pharma announce U.S. FDA approval of generic version of Jadenu Sprinkle (deferasirox granules)
22 March 2021 - Oakrum Pharma in collaboration with Aucta Pharmaceuticals announced today the U.S. approval of a generic version of ...
Posted by Michael Wonder on 22 Mar 2021
Democrats set sights on reducing drug prices, a topic long championed by Trump
21 March 2021 - Democrats are once again eyeing the budget reconciliation process to accomplish major policy goals, including reducing ...
Posted by Michael Wonder on 22 Mar 2021
Rich countries signed away a chance to vaccinate the world
21 March 2021 - Despite warnings, American and European officials gave up leverage that could have guaranteed access for billions of ...
Posted by Michael Wonder on 22 Mar 2021
Triple therapy recommended by NICE for patients with multiple myeloma
22 March 2021 - The therapy has been recommended after a confidential discount was agreed between NHS England and the drug ...
Posted by Michael Wonder on 22 Mar 2021
ATAGI statement and clinical guidance on AstraZeneca COVID-19 vaccine following EMA safety review
19 March 2021 - This statement from the Australian Technical Advisory Group on Immunisation updates advice previous provided on 16 March. ...
Posted by Michael Wonder on 22 Mar 2021
EU has 'absolutely no need' of Russia's Sputnik V vaccine, commissioner says
21 March 2021 - The European Union does not need Russia's Sputnik V vaccine for Covid-19 and can achieve immunity ...
Posted by Michael Wonder on 21 Mar 2021
TGA approves CSL - Seqirus to manufacture AstraZeneca COVID-19 vaccine in Australia
21 March 2021 - Earlier today, the Therapeutic Goods Administration approved manufacture of the AstraZeneca COVID-19 Vaccine (ChAdOx1-S) in Australia. ...
Posted by Michael Wonder on 21 Mar 2021
Washington may become the second state to distribute its own generic drugs
17 March 2021 - A bill moving through the Washington legislature may make the state only the second in the ...
Posted by Michael Wonder on 21 Mar 2021
AstraZeneca vaccine allowed by government regulators to be produced in Australia
21 March 2021 - Astra Zeneca vaccines will be produced in Australia from now on after the regulators approved doses being ...
Posted by Michael Wonder on 20 Mar 2021
PBAC Public Summary Documents (first time rejections and deferrals) - November 2020 meeting
19 March 2021 - The Public Summary Documents (first time rejections and deferrals) from the November 2020 PBAC meeting are now ...
Posted by Michael Wonder on 20 Mar 2021
FDA authorises first machine learning-based screening device to identify certain biomarkers that may indicate COVID-19 infection
19 March 2021 - Device may be used to identify biomarkers indicative of SARS-CoV-2 infection among certain asymptomatic individuals following a ...
Posted by Michael Wonder on 19 Mar 2021
Senate narrowly confirms Becerra as health secretary
18 March 2021 - Republican Sen. Susan Collins joined all of the Democrats present in the 50-49 vote. ...
Posted by Michael Wonder on 19 Mar 2021
Too fast or too slow: is the FDA moving at the right speed?
19 March 2021 - Regardless of President Joe Biden’s choice for the next commissioner of the FDA, the Senate Health, Education, ...
Posted by Michael Wonder on 19 Mar 2021
Janssen announces U.S. FDA approval of Ponvory (ponesimod), an oral treatment for adults with relapsing multiple sclerosis proven superior to Aubagio (teriflunomide) in reducing annual relapses and brain lesions
19 March 2021 - Ponvory is the first and only FDA approved oral disease modifying therapy studied against an established oral ...